Home | Database| CCM

Complimentary downloads

Star Lake Biosciences continues financial losses due to shrinking amino acid business

Keyword:
Publish time:4/23/2018 12:00:00 AM      Source: CCM
Information collection and data processing:  CCM     For more information, please contact us

On April 9, Guangdong based Star Lake Bioscience released its financial report for 2017, which revealed a revenue of more than USD100 million, up by over 1% compared to 2016. With this number, the company made losses of about USD25 million last year. The reasons for the financial loss, according to company representatives, was the increases in the costs of environmental protection and raw material.



 


According to the research of market intelligence firm CCM, Star Lake Bioscience has been making losses for the last years in a row. 


It is worth mentioning that nucleotide and amino acid production is traditionally the main source of profit for the enterprise. However, the success of those products is going down rapidly. For example, last year's share of the amino acid business was only 10.63%. As a result, amino acid feed additives contribution to the company's revenue went down by 46.44% YoY. 


Star Lake Bioscience’s amino acid business also realised a small output in 2017. According to CCM, the enterprise produced 252 tonnes of amino acid feed additives, up by 62% YoY, and 662 tonnes of amino acid APIs and intermediates, down by 40% YoY. However, the production of nucleotide additives reached 5,975 tonnes, and that of APIs and intermediates of nucleosides and nucleotides was 1,561 tonnes. 


Star Lake Bioscience now produces only valine and leucine and has not yet made a further restructuring of its amino acid business.


Business Expansion may achieve a turnaround

Despite the poor financial performance last year, Star Lake Bioscience is still planning to expand in 2018. This expansion might be the way for the company to achieve a financial turnaround. 


The company is planning to buy all shares in a company engaged in the R&D, production and sale of pharmaceutical intermediates. Notably, Star Lake Bioscience's shares were falling in the two months before a trade suspension related to the announcement. The acquisition, once finished, will possibly convince the public that Star Lake Bioscience will make a financial turnaround. 

 

About the company

Star Lake Bioscience manufactures and sells APIs, as well as food and feed additives in the and global markets. The company offers various APIs, such as inosine, guanosine, and L-proline. In addition, the company offers L-Threonine, a feed additive used in pre-mixtures, and pig and poultry feed. Star Lake Bioscience was founded in 1964 in the People’s Republic of China. 


Star Lake Bioscience achieved sales of biochemical APIs of USD46.36 million, down by 24.14%, and of USD62.29 million of food and feed additives, up by 35.63% YoY. Despite the YoY increase, the gross profit margin of the food and feed additives business was -0.03%. Given that the environmental policies in China are getting stricter, and the bio-fermentation and biochemical industries, which Star Lake Bioscience is involved in, are rapidly expanding, the company is not likely to improve its financial performance in the short term. 


About the article

The information for this article comes from CCM, China’s leading market intelligence provider for the fields of agriculture, chemicals, food and feed. 


Get regular insights into China’s amino acids market by subscribing to CCM’s monthly published report Amino Acid China News. 


Take part in the discussion by joining our relevant groups on LinkedIn and Facebook. 

Follow CCM on Twitter: @CCM_Kcomber